Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions
Yunsheng Yang(Chinese PLA General Hospital), Sam Lim(Duke-NUS Medical School), Jing‐Yuan Fang(Shanghai Institute of Hematology), Jacquelyn A. Cronin(Ironwood Pharmaceuticals (United States)), N Montreewasuwat(Duke-NUS Medical School), David S. Reasner(Ironwood Pharmaceuticals (United States)), Jing Sun(Shanghai Jiao Tong University), Xiaozhong Guo(Ministry of Ecology and Environment), Xizhong Shen(Shanghai Medical College of Fudan University), Ning Dai(Sir Run Run Shaw Hospital), Jeffrey M. Johnston(Ironwood Pharmaceuticals (United States)), Youlin Yang(Harbin Medical University), Bal Raj Bhandari(Ironwood Pharmaceuticals (United States)), Peter YF. Zeng(Western University), Mark G. Currie(Flinders University), George Zhijian Chen(AstraZeneca (Germany))
Cited by 80
Related Papers
Comprehensive review of targeted therapy for colorectal cancer
|Signal Transduction and Targeted Therapy|2020|1.7k
Selective inhibition of the inducible nitric oxide synthase by aminoguanidine
|European Journal of Pharmacology|1993|727
Development and Validation of the Rome IV Diagnostic Questionnaire for Adults
|Gastroenterology|2016|696
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
|Nature Communications|2019|427